|
Market Closed -
Hong Kong S.E.
12:08:08 21/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.1500 HKD | +2.74% |
|
+12.78% | +33.93% |
| 08-13 | Aceso Life Science Group Limited Reports Earnings Results for the Full Year Ended March 31, 2026 | CI |
| 05-05 | Aceso Life Subscribes for HK$167.3 Million of Imagi Fin Shares | MT |
Company Valuation: Aceso Life Science Group Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,224 | 1,574 | 472.4 | 1,314 | 1,174 | 369.1 |
| Change | - | 28.51% | -69.98% | 178.13% | -10.67% | -68.55% |
| Enterprise Value (EV) 1 | 3,011 | 3,660 | 2,765 | 3,634 | 3,443 | 2,458 |
| Change | - | 21.55% | -24.43% | 31.41% | -5.26% | -28.6% |
| P/E | -4.09x | -3.59x | -1.15x | -4.93x | -2.5x | -0.4x |
| PBR | 0.49x | 0.66x | 0.24x | 0.85x | 1.27x | 30.8x |
| PEG | - | -0.1x | 0.1x | 0.1x | -0x | -0x |
| Capitalization / Revenue | -7.73x | 16.1x | 2.78x | 6.35x | 107x | -5.2x |
| EV / Revenue | -19x | 37.3x | 16.3x | 17.6x | 313x | -34.6x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / EBIT | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.0491 | -0.0633 | -0.0555 | -0.0361 | -0.0635 | -0.1244 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | -158.5 | 98 | 170 | 207 | 11 | -71 |
| EBITDA | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - |
| Net income 1 | -283.7 | -376 | -370 | -264 | -462 | -895 |
| Net Debt 1 | 1,786 | 2,086 | 2,293 | 2,320 | 2,269 | 2,089 |
| Reference price 2 | 0.2010 | 0.2270 | 0.0640 | 0.1780 | 0.1590 | 0.0500 |
| Nbr of stocks (in thousands) | 6,091,887 | 6,931,887 | 7,381,777 | 7,381,777 | 7,381,777 | 7,381,777 |
| Announcement Date | 29/07/20 | 22/07/21 | 28/07/22 | 26/07/23 | 26/07/24 | 30/07/25 |
1HKD in Million2HKD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 169M | |
| 27.89x | 2.73x | 13.76x | - | 12.24B | |
| 17.38x | 1.91x | 9.71x | 1.64% | 11.78B | |
| 19.49x | 1.19x | 10.23x | 1.39% | 8.66B | |
| -13.77x | - | - | - | 459M | |
| 50.23x | 0.19x | 3.87x | - | 81.13M | |
| Average | 20.24x | 1.50x | 9.39x | 1.52% | 5.56B | |
| Weighted average by Cap. | 21.45x | 2.02x | 11.34x | 1.54% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 474 Stock
- Valuation Aceso Life Science Group Limited
Select your edition
All financial news and data tailored to specific country editions
